Gadolinium: EU nations get 1 year to implement EMA ruling

By Philip Ward, staff writer

November 27, 2017 -- The European Commission (EC) has adopted the decision of the European Medicines Agency (EMA) on linear gadolinium-based contrast agents, but with one important amendment: European Union (EU) member states will have up to a year to implement the ruling, rather than the normal two months.

This development was announced by the EC on 16 November, following a meeting of the Standing Committee on Medicinal Products for Human Use held in Brussels on 14 November. Effectively, it means some countries will choose to take only two months to implement the EMA's Pharmacovigilance Risk Assessment Committee ruling in July 2017 to suspend gadodiamide (Omniscan, GE Healthcare), gadopentetic acid (Magnevist, Bayer) and gadoversetamide (Optimark, Guerbet), whereas other nations will take up to a year.

According to the official minutes from the Brussels meeting, "Some Member States raised concerns regarding the impact of the commission decision on the availability of contrast agents in their territory. To address these concerns, the draft commission decision was amended to allow member states to defer for up to 12 months the suspension of critical products on the basis of potential unmet medical need and considering the availability of suitable alternative medicinal products."

The Standing Committee on Medicinal Products for Human Use was asked for its opinion on the amended draft commission implementing decision about the marketing authorizations of products for human use that contain gadobenic acid, gadobutrol, gadodiamide, gadopentetic acid, gadoteric acid, gadoteridol, gadoversetamide, and gadoxetic acid. It gave a favorable opinion on the draft decision, as amended during the meeting, with 19 out of 28 member states in favor, representing 70.30% of the population, the minutes noted.

7 PRAC members opposed EMA's gadolinium decision
Minutes published by the European Medicines Agency (EMA) have revealed that seven of the 34 members of the Pharmacovigilance Risk Assessment Committee...
ISMRM offers guidelines for gadolinium MRI contrast
Taking what's described as a "wait and see approach," the International Society for Magnetic Resonance in Medicine (ISMRM) has published guidelines on...
Gadolinium: PRAC modifies advice on contrast agents
After taking a long, hard, second look at the safety data of gadolinium-based MRI contrast agents, the Pharmacovigilance Risk Assessment Committee (PRAC)...
RoeKo: Macrocyclic contrast shows no signal changes
A new study of pediatric MRI safety in the brain presented at the 98th German Radiology Congress (Deutscher Röntgenkongress, RöKo 2017) has...

Copyright © 2017

Last Updated pw 11/27/2017 7:59:27 AM